

anti-Human Mirikizumab Monoclonal Antibody | anti-IL23A antibody

Research Grade Mirikizumab

CATALOG #
AAA120132

REACTIVITY
Human


PRODUCT SYNONYMS

Mirikizumab; Monoclonal Antibody; Research Grade Mirikizumab; LY-3074828; SGRF; IL-23-A; IL-23 subunit alpha; Interleukin-23 subunit p19; IL23A; Interleukin-23 subunit alpha; IL-23p19; anti-IL23A antibody

PRODUCT SPECIFICATIONS

Reactivity	Human
Clonality	Monoclonal
Isotype	IgG4-kappa
Purity/Purification	>95%; Protein A or G purified from cell culture supernatant.
Form/Format	Liquid. PBS buffer, pH7.4
Concentration	1mg/ml (varies by lot)
Host Species	Humanized
CAS	1884201-71-1
Preparation and Storage	Store at +4 degree C short term (1-2 weeks). Store at -20 degree C 12 months. Store at -80 degree C long term. Use a manual defrost freezer and avoid repeated freeze-thaw cycles.

IMAGES



SDS-PAGE

SDS PAGE for Mirikizumab

ADDITIONAL INFORMATION

Product Categories/Family for anti-IL23A antibody

Research Biosimilar

References

A SPECIAL MEETING REVIEW EDITION: Highlights in Inflammatory Bowel Disease From the 14th Congress of ECCO: A Review of Selected Presentations From the 14th Congress of the European Crohn's and Colitis Organisation (ECCO) -March 6-9, 2019 -Copenhagen, Denmark Special Reporting on -VARSITY: A Double-Blind, Double-Dummy, Randomized Controlled Trial of Vedolizumab Versus Adalimumab in Patients With Active Ulcerative Colitis-Analyses of Data From the VISIBLE 1 and 2 Trials: Vedolizumab in Patients With Ulcerative Colitis or Crohn's Disease-Improved Endoscopic Outcomes and Mucosal Healing of Upadacitinib as an Induction Therapy in Adults With Moderately to Severely Active Ulcerative Colitis: Data From the U-ACHIEVE Study Long-Term Safety of Vedolizumab in Ulcerative Colitis and Crohn's Disease: Final Results From the GEMINI LTS Study-Pediatric Crohn's Disease Adalimumab Level-Based Optimization Treatment (PAILOT) Randomized Controlled Trial-Maintenance Treatment With Mirikizumab, a P19-Directed IL-23 Antibody: 52-Week Results in Patients With Moderately to Severely Active Ulcerative Colitis-Real-World Effectiveness and Safety of Vedolizumab and Anti-TNF Therapy in Biologic-Naive Patients With Ulcerative Colitis or Crohn's Disease: Results From the EVOLVE Study-A Randomized, Multicenter, Double-Blind, Placebo-Controlled Study of a Targeted-Release Oral Cyclosporine Formulation in the Treatment of Mild to Moderate Ulcerative Colitis: Efficacy Results-Real-World Analyses of Patients With IBD Treated With Vedolizumab PLUS Meeting Abstract Summaries With Expert Commentary by: Edward V. Loftus Jr, MD Professor of MedicineDivision of Gastroenterology and HepatologyMayo ClinicRochester, Minnesota, PMID: 31632213

Anti-interleukin-12 and anti-interleukin-23 agents in Crohn's disease, PMID: 30571147

Anti-interleukin-23 agents for the treatment of ulcerative colitis, PMID: 31760827

Central Reading of Ulcerative Colitis Clinical Trial Videos Using Neural Networks, PMID: 33098883

Clinical Trials of IL-12/IL-23 Inhibitors in Inflammatory Bowel Disease, PMID: 33105016

NCBI AND UNIPROT INFORMATION

NCBI GI #	7706702
NCBI GeneID	51561
NCBI Accession #	NP_057668.1
NCBI GenBank Nucleotide #	NM_016584.2
UniProt Accession #	Q9NPF7; Q6NZ80; Q6NZ82; Q9H2A5
Molecular Weight	20,730 Da
NCBI Official Full Name	interleukin-23 subunit alpha
NCBI Official Synonym Full Names	interleukin 23, alpha subunit p19
NCBI Official Symbol	IL23A
NCBI Official Synonym Symbols	P19; SGRF; IL-23; IL-23A; IL23P19
NCBI Protein Information	interleukin-23 subunit alpha; IL-23 subunit alpha; IL-23-A; IL-23p19; JKA3 induced upon T-cell activation; interleukin 23 p19 subunit; interleukin-23 subunit p19; interleukin-six, G-CSF related factor
UniProt Protein Name	Interleukin-23 subunit alpha
UniProt Gene Name	IL23A
UniProt Synonym Gene Names	SGRF; IL-23 subunit alpha; IL-23-A; IL-23p19
UniProt Entry Name	IL23A_HUMAN

For Research Use Only. Not for use in diagnostic or therapeutic procedures. Small volumes of product may become entrapped in the seal of the vial during shipment and storage; if necessary, briefly centrifuge the vial on a tabletop centrifuge to dislodge any liquid in the cap.